The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.
One pharmacy director would like to see a lot more comparative data about new therapies.
Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.
When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.
Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?
The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.
The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.
The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.
Express Scripts and CVS Health revealed their formularies with Pfizer’s Xeljanz making the jump from excluded to preferred for Express Scripts.
States and insurers are lifting restrictions on HCV drugs; Teva’s request to join PhRMA raises eyebrows; Merck partners with GPO
Get the most out of
Register for free and enjoy unlimited access to: